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Introduction
Therapy-related leukemia is a neoplastic hematopoietic disorder arising in most cases from a multipotent stem cell and in a few cases from a lineage-committed progenitor. The terms "therapy-related myelodysplastic syndrome" (t-MDS) and "therapy-related acute myeloid leukemia" (t-AML) are used to describe a clinical syndrome that exhibits important differences from AML that arises de novo. The terms therapy-related or treatment-related leukemia are descriptive and are based on a patient's history of exposure to cytotoxic agents. They imply a causal relationship, but the mechanism remains to be established. These terms may ultimately be too restrictive, since the leukemia that develops after exposure to benzene or atomic bomb irradiation is similar or identical to the therapy-related leukemia syndrome. The term secondary leukemia correctly denotes that the disease did not develop spontaneously or de novo. However, this term is often misunderstood as indicating merely that the leukemia occurred as the second cancer in time or evolving from the primary malignancy, and not necessarily related to the treatment of the first cancer. In the future, as various subtypes of leukemia are distinguished by specific genetic alterations, the terms de novo (or primary) and therapy-related leukemia will likely be discarded and specific etiologies incorporated into the diagnostic nomenclature.
Mutations and Leukemogenesis
The development of therapy-related secondary neoplasms provides a unique, ethically acceptable environment for studying the effects of mutagens on carcinogenesis in humans. Koeffler (3) . Table 3 shows the distribution of cytogenetic abnormalities observed in 240 patients with therapy-related leukemia studied at the University of Chicago. The most common single abnormality is monosomy 7, followed in frequency by deletion of the long arm of chromosome 5 [del(5q)] and by monosomy 5. These same abnormalities are observed in primary MDS and AML de novo, especially in older patients (11, (13) (14) (15) (16) (17) (18) (19) . In contrast to classic t-AML, these leukemias have a much shorter latency between initiation of chemotherapy for the primary cancer and the development of leukemia (Table 4 ). In addition, a preceding myelodysplastic syndrome is not associated with these leukemias. The 1 1q23 cases primarily have monoblastic (M5) or myelomonocytic (M4) phenotypes, but cases of AML-M1 and M2 as well as acute lymphoblastic leukemia (ALL) have been described. The 21 q22 cases are typically AML M2 (19, 20) . The response to chemotherapy in this newer syndrome of therapyrelated leukemia also differs from classic t-AML and is more favorable.
A consistent pattern has emerged of prior treatment with inhibitors of topoisomerase II either alone or in combination with alkylating agents. At first, the association was linked only to the epipodophyllotoxins, etoposide, and teniposide (16, 17) . However, subsequent reports have also implicated DNA intercalating agents such as doxorubicin, 4-epi-doxorubicin, mitoxantrone, and actinomycin D (18, 21) .
The Role of 1 1 q23 Translocations
Chromosome 1 1q23 translocations occur in both de novo and therapy-related leukemia. These translocations affect 7 to 10% of patients with ALL de novo, with the t(4; I 1) (q2 1;q23) and the t (1 1; 19 ) (q23;pl3.3) predominating, and 5-6% of AML de novo with t(6;1 1)(q27;q23), t(9;1 1)(p22;q23), and t(1 1;19)(q23;p13.1) being the most common. The ALL patients are usually FAB Li, but in addition to the usual B-cell markers, they often express myeloid or monocytoid markers. The AML patients are typically myelomonocytic (M4) or monoblastic (M5) and often coexpress lymphoid markers. In both AML and ALL with 1 q23 translocations, the patients often present with hyperleukocytosis and early central nervous system involvement. The clinical presentation, morphology, and immunophenotype of therapy-related leukemias with 1 1q23 translocations are indistinguishable from de novo cases.
Therapy-related Acute Lymphoblastic Leukemia
The classic syndrome of therapy-related leukemia with aberrations involving chromosomes 5 and 7 has exclusively involved the myeloid lineage. The initial case reports of therapy-related leukemia with 1 1 q23 translocations, predominantly with the t(9;1 1), were also myeloid leukemias, albeit usually of a monoblastic phenotype (17) . However, given the involvement of 1 1q23 in both myeloid and lymphoblastic acute leukemias that occur de novo, it should not be surprising that therapy-related lymphoblastic leukemias have also been described. In 1985 Secker-Walker et al. (22) reported on a child with neuroblastoma who was treated with a multi-drug regimen that included doxorubicin and teniposide; ALL with a t(4;11) developed 12 months after completion of therapy (22) . In 1988 Archimbaud et al. (23) reported on the development of ALL with a t(4;1 1) in two breast cancer patients treated with doxorubicin-containing regimens. Several other cases of therapy-related ALL have been described since that time. In an interesting recent report by Jonveaux et al. (24) , a patient initially treated for an acute monoblastic leukemia de novo with a t(6; 1 1) (q27;q23), subsequently developed ALL with a t(4;1 1) (24) . Different predated the widespread use of hematopoietic growth factors. The unexpected rate of t-AML in this trial has raised the concern that growth factors may be synergistic with chemotherapy in inducing t-AML. However, no data outside of this trial exist yet to examine this issue further.
Different Genetic Mechanisms for Leukemogenesis
The particular mechanisms of DNA damage that lead either to chromosomal deletions or to balanced translocations may underlie the differences in latencies between the two forms of therapy-related leukemia (15 (27) . MLL gene rearrangements were detected in 58 of the 61 leukemia patients and in 3 of the 20 lymphoma patients. This included all patients with the five common 1 lq23 translocations mentioned earlier plus 16 uncommon 1lq23 rearrangements that involved the MLL gene, for a total of 21 different chromosomal abnormalities that affect the MLL gene. All of the breaks occurred in an 8.3-kb pair genomic BamHI fragment.
Several genes at breakpoints on the partner chromosomes involved in 1 lq23 translocations have been cloned. These include AF-4 in the t(4; 11) (q21;q23), ENL in the t(l 1; 19)(q23;p13.3), AF-9 in the t(9;11)(p22;q23), AF-6in the t(6;11) (q27;q23), AF-lp in the t(I;1 l)(p32;q23), AF-I0 in the t(1O;11)(pl2;q23), AF-17 in the t(l 7; 11) (q21 ;q23), and AF-X in the t(X;1 1)(q13;q23). The functions of these genes have not yet been determined. Thirman et al. (28) recently cloned the gene ELL that fuses to MLL in the t(I 1; 19) (q23;p13.1), a recurring abnormality in AML as well as one of the most common breakpoints in topoisomerase II induced t-AML (28) . This translocation is distinct from another type of 11; 19 translocation with a 19pl3.3 breakpoint that results in the fusion of MLL to the ENL gene. ELL is not homologous to other MLL partner genes. Because 11 q23 translocations always result in the generation of in-frame fusion transcripts, the sequences contributed from these partner genes may be essential to leukemogenesis.
The AMLI gene at chromosome band 21q22 also fuses to genes at multiple chromosomal breakpoint regions, albeit many fewer than MLL (19, 20) . Nucifora and coworkers (19, 20, 29) have identified complex intergenic splicing between the AMLI gene and either EAP, MDSI, or EVII within chromosome band 3q26 in the t(3;21). AMLI also fuses with ETO at 8q22 in the t(8;21) in both de novo and therapy-related cases.
Conclusions
As the numbers of cancer survivors increase after conventional cytotoxic treatment, the incidence of therapy-related leukemia will undoubtedly rise. It is imperative that the leukemogenic potential of current multiagent treatment regimens for malignant and nonmalignant disorders be considered prospectively in primary treatment planning and be reduced, if possible. As further understanding about mechanisms of mutagenesis accumulates, it is likely that certain individuals who have increased susceptibility to the leukemogenic activity of particular agents can be identified. Prevention of this complication of cancer treatment is a clinical and scientific challenge, but it is clearly the appropriate goal.
